Page 108 - Haematologica - Vol. 105 n. 6 - June 2020

L. Mazzarella et al.
Santos-Silva I, Leon DA, Smeeth L. Body- mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 mil- lion UK adults. Lancet. 2014;384(9945):755- 765.
7. American Cancer Society. Leukemia–Acute Myeloid (Myelogenous). http://www.can- cer.org/cancer/leukemia- acutemyeloidaml/detailedguide/leukemia- acute-myeloid-myelogenous-risk-factors.
8. Komanduri K V, Levine RL. Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification. Annu Rev Med. 2016;67:59-72.
9. Coombs CC, Tavakkoli M, Tallman MS. Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J. 2015;5:e304.
10. Breccia M, Mazzarella L, Bagnardi V, et al. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. Blood. 2012;119(1):49-54.
11. Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.
12. Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long- term results and role of maintenance. Blood. 2011;117(18):4716-4725.
13. Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA- 2000 trial of the GIMEMA Group. Blood. 2010;116(17):3171-3179.
14. Adès L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a compari-
son of French-Belgian-Swiss and PETHEMA
results. Blood. 2008;111(3):1078-1084.
15. Yaari G, Bolen CR, Thakar J, Kleinstein SH. Quantitative set analysis for gene expres- sion: A method to quantify gene set differ- ential expression including gene-gene corre- lations. Nucleic Acids Res. 2013;41(18):1-11. 16. Morishima K, Tanabe M, Furumichi M, Kanehisa M, Sato Y. KEGG: new perspec- tives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2016;45(D1):
D353-D361.
17. Gonzalez-Perez A, Perez-Llamas C, Deu-
Pons J, et al. IntOGen-mutations identifies cancer drivers across tumor types. Nat Methods. 2013;10(11):1081-1082.
18. Wang D, Dubois RN. Eicosanoids and can- cer. Nat Rev Cancer. 2010;10(3):181-193. 19. Castillo JJ, Mulkey F, Geyer S, et al.
Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials. Am J Hematol. 2016;91(2):199-204.
20. Wong O, Harris F, Yiying W, Hua F. A hospi- tal-based case-control study of acute myeloid leukemia in Shanghai: Analysis of personal characteristics, lifestyle and envi- ronmental risk factors by subtypes of the WHO classification. Regul Toxicol Pharmacol. 2009;55(3):340-352.
21. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia. 1997;11(10):1661-1664.
22. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the dis- tribution of body mass index among US adults, 1999-2010. JAMA. 2012;307(5):491- 497.
23. Matasar MJ, Ritchie EK, Consedine N,
Magai C, Neugut AI. Incidence rates of acute promyelocytic leukemia among Hispanics, blacks, Asians, and non-Hispanic whites in the United States. Eur J Cancer Prev. 2006;15(4):367-370.
24. Caspar-Bauguil S, Fioroni A, Galinier A, et al. Pro-inflammatory phospholipid arachi- donic acid/eicosapentaenoic acid ratio of dysmetabolic severely obese women. Obes Surg. 2012;22(6):935-944.
25. Trabanelli S, Chevalier MF, Martinez- Usatorre A, et al. Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat Commun. 2017;8(1):593.
26. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxi- some proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 1995;83(5):813-819.
27. Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated recep- tors in carcinogenesis and chemoprevention. Nat Rev Cancer. 2012;12(3):181-195.
28. Poloz Y, Stambolic V. Obesity and cancer, a case for insulin signaling. Cell Death Dis. 2015;6:e2037.
29. Dahlén SE, Björk J, Hedqvist P, et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci U S A. 1981;78(6):3887-3891.
30. Stockard B, Garrett T, Guingab-Cagmat J, Meshinchi S, Lamba J. Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia. Sci Rep. 2018;8(1):5534.
31. Moskal A, Pisa PT, Ferrari P, et al. Nutrient Patterns and Their Food Sources in an International Study Setting: Report from the EPIC Study. PLoS One. 2014;9(6):e98647.
1566
haematologica | 2020; 105(6)